LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Hamd, Mohamed A El"
  2. AU=Oorni Katariina AU=Oorni Katariina
  3. AU="Condel, Laura"
  4. AU="Biccler, Jorne"
  5. AU="Matthias Harbers"
  6. AU="Yang, Yuantong"
  7. AU="Carstens, Elma"
  8. AU="Wu, Xiaoxing"
  9. AU="Sato, Marika"
  10. AU="Rautiala, Petri"
  11. AU="Lin, Liqin"
  12. AU="Deborah Jean McClelland"
  13. AU="Brar, Ajit"
  14. AU="Aniyan Kumbalaparambil, Yesoda"
  15. AU=Carolan Michael
  16. AU="Pojskić, Mirza"
  17. AU="Tsujimoto, Sakura"
  18. AU=Di Tano Giuseppe
  19. AU="Khan, Sobia"
  20. AU="Kao, Yu-Yin"
  21. AU="Katerina Demnerova"
  22. AU="Sorrentino, I"
  23. AU="Pogge von Strandmann, Elke"
  24. AU="Lenzi, Kerry A"
  25. AU="Sakakura, Akira"
  26. AU="Nowell, Sian"
  27. AU="Mirko Cortese"
  28. AU="Klein, Steffen"
  29. AU="Koike, Toru"
  30. AU="Hung, Chung-Yu"
  31. AU="Muendlein, Hayley I"
  32. AU="Papavramidis, Theodosios"

Suchergebnis

Treffer 1 - 4 von insgesamt 4

Suchoptionen

  1. Artikel ; Online: Self-assembling Organogels Loaded with Tenoxicam for Local Intensive Pain and Inflammation Cure: In Vitro and In Vivo Correlation.

    Osman, Shaaban K / Yassin, Taher M / Abdelzaher, Arafat / Ahmed, Fatma / Mohammed, Ahmed M / Abdellatif, Ahmed A H / Saleh, Khalid I / Mahdi, Wael A / Alshehri, Sultan / Hamd, Mohamed A El / Sarhan, Hatem

    AAPS PharmSciTech

    2024  Band 25, Heft 1, Seite(n) 18

    Abstract: Due to tenoxicam (TX)'s poor aqueous solubility (0.072 mg/ml), it is poorly absorbable in the GIT, and the long-term oral administration of TX may cause severe GIT disturbances. Topical administration of TX can help in bypassing the GIT adverse effects. ... ...

    Abstract Due to tenoxicam (TX)'s poor aqueous solubility (0.072 mg/ml), it is poorly absorbable in the GIT, and the long-term oral administration of TX may cause severe GIT disturbances. Topical administration of TX can help in bypassing the GIT adverse effects. Therefore, in the present work, we constructed different pluronic/lecithin organogels (PLOs) for topical delivery of TX. PLO was constructed simply via direct mixing of an aqueous pluronic solution with lecithin solution. The prepared PLO formulations were characterized for their physicochemical properties including pH, drug content, visual inspection, viscosity, and spreadability. Also, the in vitro release and kinetic studies were carried out to investigate the mechanism of drug release. Moreover, the in vivo studies were carried out by investigating the anti-inflammatory and analgesic activities using albino male rats. The results showed that the modified PLOs have good physicochemical properties. The viscosity of the modified gels is a direct proportionality with both lecithin and pluronic concentrations. Also, subsequently, the drug release rate is directly proportional to gel viscosity. Moreover, the in vivo studies showed that the modified PLOs (F19) showed a significant ( < 0.05%) paw edema inhibition and pain analgesia compared with other investigated groups. Also, the results indicated that the increase in dose is accompanied by higher activity and a longer duration of action which extended to 12 h. Hence, the modified PLOs are promising safe candidates or vehicles for effective TX loading with sustained delivery behavior.
    Mesh-Begriff(e) Animals ; Rats ; Kinetics ; Lecithins ; Poloxamer ; Inflammation ; Pain ; Piroxicam/analogs & derivatives
    Chemische Substanzen tenoxicam (Z1R9N0A399) ; Lecithins ; Poloxamer (106392-12-5) ; Piroxicam (13T4O6VMAM)
    Sprache Englisch
    Erscheinungsdatum 2024-01-23
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 2052070-0
    ISSN 1530-9932 ; 1530-9932
    ISSN (online) 1530-9932
    ISSN 1530-9932
    DOI 10.1208/s12249-024-02742-9
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  2. Artikel: Formulation development of lipid polymer hybrid nanoparticles of doxorubicin and its

    Shafique, Muhammad / Ur Rehman, Maqsood / Kamal, Zul / Alzhrani, Rami M / Alshehri, Sameer / Alamri, Ali H / Bakkari, Mohammed Ali / Sabei, Fahad Y / Safhi, Awaji Y / Mohammed, Ahmed M / Hamd, Mohamed A El / Almawash, Saud

    Frontiers in pharmacology

    2023  Band 14, Seite(n) 1025013

    Abstract: The purpose of this study was to assess the parameters of doxorubicin (DOX) loaded lipid polymer hybrid nanoparticles (LPHNs) formulation development, and then the bioavailability of DOX were determined in the rabbit model, in order to evaluate the ... ...

    Abstract The purpose of this study was to assess the parameters of doxorubicin (DOX) loaded lipid polymer hybrid nanoparticles (LPHNs) formulation development, and then the bioavailability of DOX were determined in the rabbit model, in order to evaluate the intrinsic outcome of dosage form improvement after the oral administration. LPHNs were prepared by combine approach, using both magnetic stirring and probe sonication followed by its characterization in terms of size-distribution (Zeta Size), entrapment efficiency (EE), loading capacity, and the kinetics of DOX. LPHNPs were further characterized by using scanning electron microscopy (SEM), powder X-Ray diffractometry (P-XRD), Fourier transform infrared spectroscopy (FT-IR), differential scanning calorimetry (DSC),
    Sprache Englisch
    Erscheinungsdatum 2023-02-07
    Erscheinungsland Switzerland
    Dokumenttyp Journal Article
    ZDB-ID 2587355-6
    ISSN 1663-9812
    ISSN 1663-9812
    DOI 10.3389/fphar.2023.1025013
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  3. Artikel ; Online: A Novel Approach for the Availability and Ocular Delivery of Tenoxicam Potassium: Synthesis, Characterization, and In Vivo Application.

    Osman, Shaaban K / Yassin, Taher M / Mohammed, Ahmed M / Alfayomy, Abdallah M / Abdellatif, Ahmed A / Mahdi, Wael A / Alshehri, Sultan / Hamd, Mohamed A El / Sarhan, Hatem / Ibrahim, Mohammed A

    AAPS PharmSciTech

    2023  Band 24, Heft 1, Seite(n) 44

    Abstract: Tenoxicam (TX) is a non-steroidal anti-inflammatory agent that can be used to control pain in various ophthalmic lesions like cataracts, refractive surgery, and corneal abrasion. TX has a very slightly aqueous solubility of 0.072 mg/mL resulting in ... ...

    Abstract Tenoxicam (TX) is a non-steroidal anti-inflammatory agent that can be used to control pain in various ophthalmic lesions like cataracts, refractive surgery, and corneal abrasion. TX has a very slightly aqueous solubility of 0.072 mg/mL resulting in difficulty to be formulated in ophthalmic solutions. This study aims to improve TX solubility by converting it into its potassium salt to achieve a target of 10 mg/mL (1%w/v) concentration of TX in the desired aqueous medium for the formulation of aqueous ophthalmic solutions. The synthesized TX salt was characterized by different evaluation parameters such as solubility studies,
    Mesh-Begriff(e) Animals ; Male ; Rabbits ; Drug Delivery Systems/methods ; Piroxicam ; Anti-Inflammatory Agents, Non-Steroidal ; Ophthalmic Solutions
    Chemische Substanzen tenoxicam (Z1R9N0A399) ; Piroxicam (13T4O6VMAM) ; Anti-Inflammatory Agents, Non-Steroidal ; Ophthalmic Solutions
    Sprache Englisch
    Erscheinungsdatum 2023-01-26
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 2052070-0
    ISSN 1530-9932 ; 1530-9932
    ISSN (online) 1530-9932
    ISSN 1530-9932
    DOI 10.1208/s12249-022-02487-3
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  4. Artikel: Design, Synthesis, Biological Evaluation, and Molecular Dynamics Studies of Novel Lapatinib Derivatives.

    Elkamhawy, Ahmed / Son, Seohyun / Lee, Hwa Young / El-Maghrabey, Mahmoud H / Hamd, Mohamed A El / Alshammari, Saud O / Abdelhameed, Abeer A / Alshammari, Qamar A / Abdeen, Ahmed / Ibrahim, Samah F / Mahdi, Wael A / Alshehri, Sultan / Alnajjar, Radwan / Choi, Won Jun / Al-Karmalawy, Ahmed A / Lee, Kyeong

    Pharmaceuticals (Basel, Switzerland)

    2022  Band 16, Heft 1

    Abstract: Co-expression of the epidermal growth factor receptor (EGFR, also known as ErbB1) and human epidermal growth factor receptor 2 (HER2) has been identified as a diagnostic or prognostic sign in various tumors. Despite the fact that lapatinib (EGFR/HER2 ... ...

    Abstract Co-expression of the epidermal growth factor receptor (EGFR, also known as ErbB1) and human epidermal growth factor receptor 2 (HER2) has been identified as a diagnostic or prognostic sign in various tumors. Despite the fact that lapatinib (EGFR/HER2 dual inhibitor) has shown to be successful, many patients do not respond to it or develop resistance for a variety of reasons that are still unclear. As a result, new approaches and inhibitory small molecules are still needed for EGFR/HER2 inhibition. Herein, novel lapatinib derivatives possessing 4-anilinoquinazoline and imidazole scaffolds (
    Sprache Englisch
    Erscheinungsdatum 2022-12-28
    Erscheinungsland Switzerland
    Dokumenttyp Journal Article
    ZDB-ID 2193542-7
    ISSN 1424-8247
    ISSN 1424-8247
    DOI 10.3390/ph16010043
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang